Προβλήματα υγείας μετα μαστεκτομη και χημειοθεραπεια
Γυναίκα 45 ετων που χειρουργήθηκε για καρκινο μαστου προ τετραετιας και με τη χημειοθεραπεία μπηκε στην εμμηνόπαυση. Εχει νοσο Hashimoto,παθαινει ουρολοιμώξεις και εχει υπερβολικα εντονες εξάψεις.Στο ιστορικο της επισημαίνεται το ότι δεν θήλασε καθολου και στα 3 της παιδιά λόγω έντονου άγχους, αραιομηνορροια και δυσμηνόρροια,ληψη αντισυλληπτικών επι πολλα έτη,αιμορροϊδες και εντονη ακμη που καταπιεσθηκαν με φάρμακα.
Με την καταλληλη ομοιοπαθητική αγωγή αποκατασταθηκε λειτουργικά ο θυρεοειδής ,σταματησαν οι ουρολοιμώξεις και περιορισθηκαν σημαντικά οι εξάψεις.
ΟΜΟΙΟΠΑΘΗΤΙΚΗ ΨΥΧΟΣΩΜΑΤΙΚΗ και ΣΩΜΑΤΟΨΥΧΙΚΗ ΘΕΡΑΠΕΙΑ
ΑΓΧΟΣ- ΦΟΒΙΕΣ- ΚΑΤΑΘΛΙΨΗ- ΠΑΝΙΚΟΣ
ΕΙΔΙΚΕΣ ΦΑΣΕΙΣ ΤΗΣ ΖΩΗΣ
Εφηβικη ηλκία, Κλιμακτήριος, Τρίτη ηλικία, Χωρισμοί,Αλλαγές στον τρόπο ζωής,Εντατική Εργασία,Σοβαρές ασθένειες,Ατυχήματα,Ανασφάλειαπερισσότερα
Homeopathic treatment for pancreatic cancer
Homeopathy is one of the most popular holistic systems of medicine. The selection of remedy is based upon the theory of individualization and symptoms similarity by using holistic approach. This is the only way through which a state of complete health can be regained by removing all the sign and symptoms from which the patient is suffering. The aim of homeopathy is not only to treat pancreatic cancer but to address its underlying cause and individual susceptibility. As far as therapeutic medication is concerned; several homeopathy medicines are available for pancreatic cancer symptoms treatment that can be selected on the basis of cause, location, sensation, modalities and extension of the complaints. For individualized remedy selection and treatment, the patient should consult a qualified homeopathic doctor in person
While conventional treatments like chemotherapy or radiation therapy helps in faster removal of cancer, Homeopathy Treatment for pancreatic cancer can help in
Regression of pancreatic cancer
Prevention of recurrence of pancreatic cancer,
Removing side-effects of chemo and radiation therapy,
Relieving cancer pains
Improving general quality of life and hence, a better reaction to other treatments
The stages of pancreatic cancer are as follows:-
Stage 0:- In stage 0, abnormal cells are found in the lining of the pancreas. These abnormal cells may become cancer cells and spread into nearby normal tissue. Stage 0 is also called carcinoma in situ.
Stage I: – In stage I, cancer has formed and is found in the pancreas only. Based on the size of the tumor stage I is further divided into: – Stage IA and Stage IB.
Stage IA: The tumor is 2 centimeters or smaller than this.
Stage IB: The tumor is larger than 2
Stage II: – In stage II, cancer may have spread to nearby tissue and organs, and may have spread to lymph nodes near the pancreas. Based on spread of the cancer, stage II is further divided into: – Stage IIA and Stage IIB,
Stage IIA: – Cancer has spread to nearby tissue and organs but has not spread to nearby lymph nodes.
Stage IIB: – Cancer has spread to nearby lymph nodes and may have spread to nearby tissue and organs.
Stage III: – In stage III, cancer has spread to the major blood vessels near the pancreas and may have spread to nearby lymph nodes.
Stage IV: – In stage IV, cancer may be of any size and has spread to distant organs, (such as the liver, lung, and peritoneal cavity). It may have also spread to organs and tissues near the pancreas or to lymph nodes
Primary Homeopathic Treatment of Cancers of the Pancreas, Stomach, Gallbladder, and Liver
Psorinum therapy shows promise in treatment of advanced disease
Chatterjee A, Biswas J, Chatterjee AK, Bhattacharya S, Mukhopadhyay B, and Mandal S. Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study. Evid Based Complement Alternat Med. 2011;2011:724743.
Non-randomized, observational, single-arm trial considering Psorinum therapy in treatment of advanced pancreatic adenocarcinoma, gastric adenocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma
158 total subjects (44 with pancreatic adenocarcinoma, 42 with gastric adenocarcinoma, 40 with gallbladder adenocarcinoma, and 32 with hepatocellular carcinoma); 25% were diagnosed with stage III and 71% with stage IV disease.
histopathology/cytopathologic confirmation of malignancy,
inoperable tumors, and
no prior chemotherapy or radiation treatment.
Psorinum 6X was administered, up to 0.02 ml/Kg body weight orally (as liquid drops under the tongue) once daily for all participants. Conventional (eg, infection and pain control, electrolyte balancing, abdominal/pleural paracentesis) and homeopathic (ie, administration of homeopathic medicines on pathological indications) supportive measures were also administered.
Results of this study, which demonstrate a 19-38-fold improvement compared to conventional treatment in five-year survival of non-resectable pancreatic cancer are, to put it mildly, intriguing.
Primary outcome measures were radiological tumor response and survival at 1, 2, 3, 4 and 5 years. Secondary outcome measure was assessment of side effects of Psorinum 6X.
Complete tumor response occurred in 33.33% of those diagnosed with stage III disease and 10.71% of those with stage IV. Partial response occurred in 41.03% and 33.93% respectively.
Five-year survival rates were 38.64% (pancreatic), 38.1% (gastric), 37.5% (gallbladder), and 43.75% (liver).
No adverse effects of Psorinum were observed, though a few participants had mild oral irritation and skin itching.
The cancer types considered in this study are among the most intractable and deadly malignancies. Conventional treatment of these conditions, though improving, is still of very limited effectiveness. For instance, in the last decade with the use of the standard first-line therapy gemcitabine, median overall survival for advanced pancreatic adenocarcinoma has increased from 3–4 months to 5–8 months,1 while 5-year survival of the non-resectable form is nearly unchanged at a dismal 1–2%.2,3 Roughly 80% of all pancreatic malignancies are inoperable at diagnosis.4 Therefore, results of this study, which demonstrate a 19–38-fold improvement compared to conventional treatment in five-year survival of non-resectable pancreatic cancer are, to put it mildly, intriguing.
Similar improvements in survival rates with Psorinum therapy were demonstrated in the other cancer types studied.
Caution should be taken, however, in interpreting these findings. Promising phase II trials are notorious for disappointing in the phase III setting. Independent verification in a controlled context is needed before an unqualified recommendation can be made.
Nevertheless, considering the very poor response of these cancers to conventional treatment and the apparent lack of toxicity and potential benefit of Psorinum therapy, it seems reasonable that clinicians with oncologic experience might offer this therapy to their patients on an individual basis.
Common homeopathic medicines such as Lycopodium 200C and Baryta carbonicum 200C were used supportively and prescribed on a pathologic (as opposed to individualized) basis. This is an important feature, as the complexity of individualized homeopathic prescribing is an obstacle both to its reproducibility in independent trials and its broad clinical adoption.
A phase III trial comparing Psorinum 6X plus conventional and homeopathic supportive care to 1) conventional treatment and 2) Psorinum 6X plus conventional (but not homeopathic) supportive care in treatment of advanced pancreatic cancer is currently underway.
2 New Studies Demonstrate Significant Effectiveness of Homeopathy in Treatment and Palliation of Cancer
Posted on February 26, 2011 by cricjohnson
Two important studies have recently been published concerning the use of homeopathy in cancer – one demonstrating greater effectiveness in certain types of cancers than any treatment yet assessed by modern research methods. Both involved relatively large numbers of participants and together represent a significant step forward, as research data in this area has been limited.
The first study  looked at primary homeopathic treatment of cancer – meaning, treatment with the intent to cure without the use of conventional oncologic treatment. The second study  looked at the effect of homeopathy on the quality of life in cancer patients receiving concomitant conventional care. Both studies had very impressive results.
In fact, the results of the first study are far and away the most robust of any therapy (conventional or holistic) yet assessed in treatment of pancreatic, gallbladder, liver, and stomach cancers. If replicated in further studies the protocol would represent a true breakthrough in treatment of these intractable malignancies – greatly increasing the survival and quality of life of these patients.
This was a non-randomized, observational trial conducted at the Critical Cancer Management Research Centre and Clinic located in Kolkata, India.
The findings were first presented at the 2009 American Society of Clinical Oncologists (ASCO) Annual Conference. ASCO is the world’s leading professional cancer organization. An abstract of the study was published in the Journal of Clinical Oncology.
Lead investigator Aradeep Chatterjee is an ASCO member and on staff at the Critical Cancer Management Research Centre and Clinic. Co-investigator Jaydip Biswas is also an ASCO member and is Director of the National Cancer Institute, Kolkata, India. Other investigators included researchers at the National Cancer Institute, Kolkata and the National Institute of Technology, Durgapur.
158 subjects participated, with the following distribution of cancer types – 42 stomach (gastric adenocarcinoma), 40 gallbladder (adenocarcinoma), 44 pancreas (adenocarcinoma) and 32 liver (hepatocellular carcinoma).
Inclusion criteria for participants were: 1) histopathalogic/cytopathologic confirmation of malignancy, 2) inoperable tumors, and 3) no prior chemotherapy or radiation therapy.
24.9% of subjects were diagnosed at stage III and 70.9% at stage IV – meaning, nearly all had locally advanced or metastatic disease.
The protocol involved the use of the homeopathic remedy Psorinum in a 6X potency. All subjects received this remedy daily along with supportive homeopathic and conventional care.
Examples of conventional supportive care include control of infection, pain, electrolyte balance, bleeding, etc. Homeopathic supportive care consisted of the use of homeopathic remedies prescribed on a pathological (as opposed to the more common patient-individualized) basis. Most remedies were in the 200C potency, with a few as mother tinctures. Examples include Baryta carbonicum 200C, Lycopodium 200C and Thuja occidentalis mother tincture.
The results were astonishing, with survival rates many times greater than that achieved with conventional treatment or any other type of rigorously assessed cancer care.
For instance, the 5 year survival rate of patients receiving conventional treatment for stage III and IV pancreatic adenocarcinoma, the most deadly of all common malignancies, is approximately 1-2%  . In this study 38.6% survived 5 years.
Hepatocellular carcinoma (liver cancer) has a 1 year survival rate of 20% and a 3 year survival rate of 5% with conventional treatment . Of the subjects receiving the Psorinum protocol 81% survived 1 year, and 59% survived 3 years. An astounding 43.75% survived 5 years.
38.1% of patients in the study having gastric adenocarcinoma survived 5 years, while conventional care achieves less than 20% 5 year survival .
Considering the study group as a whole, 33% of those with stage III disease had a complete tumor response – meaning, complete disappearance of all cancerous lesions (tumors) without disease progression or appearance of any new lesions. 41% had radiologic partial response – meaning, at least 30% shrinkage of tumors.
Among those with stage IV disease, 10.7% had complete, and 34% partial tumor response.
In addition to increased survival rates, quality of life was also significantly improved compared to standard care. 60% of those with stage III disease and 45% of those with stage IV reported that “the therapy was effective in reducing their cancer-related pain, cough, dyspnea, nausea and vomiting, fatigue, constipation and improving appetite and weakness.”
Further, “no adverse side effects were observed from the drug Psorinum. However, very few patients reported to have mild oral irritation and skin itching which were successfully controlled by supportive care.”
At the 2010 ASCO Annual Conference, Chatterjee and Biswas presented results of a similar trial – use of the same Psorinum protocol with 95 patients having inoperable lung cancer (non-small cell cancer of the lung – the most common type)  Outcomes in this trial were similar with a 5 year survival rate of 44%. This is compared to 16% with conventional treatment . Again, the abstract was published in the Journal of Clinical Oncology. The full study is not yet published.
One more trial,  using the same Psorinum protocol in treatment of advanced esophageal carcinoma was published in the Proceedings of the 2011 ASCO Annual Conference and later presented at the 2012 ASCO Gastrointestinal Cancers Symposium. [here] Of 65 participants, 17% had full and 31% had partial tumor responses. 68% survived 1 year and 26% survived 5 years. The average 5 year survival rate for non-resectable esophageal carcinoma treated conventionally is around 1%.  
Taken together, data from these three trials demonstrate a very high level of effectiveness of Psorinum therapy along with supportive conventional and homeopathic care in some of the most difficult-to-treat common malignancies.
Though the trials were not randomized or controlled, the data are noteworthy for a number of reasons: 1) the extraordinary degree of effectiveness of the treatment in these difficult to treat conditions – no published study has demonstrated anything even close to these results, 2) survival rate as an outcome measure is completely objective and therefore not subject to assessment bias, 3) there already exists a very large body of data demonstrating the degree of effectiveness of conventional treatment of these cancers – data which is consistent across all cultures and types of patients – which gives a valid basis for comparison and 4) the trials comprise a fairly large study group, with 318 total subjects.
The primary limitation of the studies is the lack of control for the effects of the supportive homeopathic care. We already know what to expect from supportive conventional care, so it is not much of a variable. However, we are left wondering how much of the effectiveness was due to the Psorinum therapy itself versus the supportive homeopathic remedies which were extensively used.
In a personal correspondence, Dr. Chatterjee indicated there would be a phase III (larger, controlled) clinical trial as a follow up to the studies – comparing the full Psorinum protocol versus 1) conventional cancer treatment, and 2) Psorinum protocol minus the homeopathic supportive care (in other words, Psorinum 6X along with only the conventional supportive care) in treatment of pancreatic adenocarcinoma. In August 2011, the Times of India reported that Chatterjee had signed a “mutual confidentiality agreement” with MD Anderson Cancer Center (at the University of Texas, Houston) to collaborate on further clinical trials.
The second study was lead by doctors at University Hospital Zurich (Switzerland), University Hospital Freiburg (Germany) and the Tumor Biology Center at Albert Ludwig’s University Freiburg (Germany). It was published in the journal BMC Cancer.
This trial aimed to assess the effects of homeopathy as an adjunct to conventional oncologic care versus conventional care alone. There were 259 subjects in the homeopathic/conventional group and 380 in the conventional-only cohort. It should be noted that 10% of those in the homeopathic group refused recommended conventional care.
The most frequent cancer type was breast cancer. Colorectal and prostate cancers as well as melanoma were also prevalent.
The primary outcome measure was change in quality of life. Secondary outcome measures were change in fatigue, psychological wellbeing and patient satisfaction. All of these parameters were measured using widely accepted assessment tools.
The type of homeopathy used was the traditional “constitutional” approach, in which a single remedy is chosen based on individualized characteristics (as opposed to common pathological or medical indications).
Patients were assessed at 3 and 12 months.
The following data emerged in the homeopathic group:
Quality of life improved significantly at 3 months and further at 12 months – twice as much as the conventional group – in the upper range of the clinical significance scale
Mental and physical fatigue and physical activity improved significantly at 3 and 12 months
Anxiety and depression did not change
The following data emerged in the conventional group:
Quality of life was slightly improved at 12 months – at the bottom edge of the clinical significance scale
Fatigue did not change
Anxiety and depression did not change
This trial was meant to reflect real-world medical practice and decision-making (by patients and doctors). The participants were not randomized and were free to choose their course of treatment. Doctors were free to recommend individualized treatment protocols.
Although the 2 groups were well-matched at entry to the study in terms of symptoms, there were important disparities, namely, 1) demographics – the homeopathic group was more likely to have a higher level of post-graduate education and to be white collar workers or self-employed, 2) stage of disease progression – the homeopathic group was more likely to have a more severe diagnosis or progressed tumor stage, and had a longer elapsed time since first diagnosis, and 3) types of therapies used – the homeopathic group used less chemotherapy and radiation, due to already having utilized more prior to study entry.
These differences precluded statistically valid comparison of the two groups as matched pair controls. Nevertheless, the data clearly suggests that homeopathic treatment is beneficial to cancer patients as a whole.
If anything, the differences should have favored a greater improvement in the conventional group – the participants were at earlier stage of illness and therefore more amenable to treatment. Some would argue that greater results are to be expected from a sicker population (the homeopathic group) who have more potential for improvement. While this may be true in non-degenerative or self-limiting conditions, it is certainly not the case in cancer, where advanced progression of disease is nearly always associated with worse symptom scores and poorer response to treatment.
Some would argue the conventional group fared worse due to greater exposure to chemotherapy and radiation – but these interventions would have been finished primarily in the first few months, and outcomes at 12 months should not have been negatively influenced by the side effects of these therapies. Indeed, one of the primary goals of conventional treatment is decreased symptom severity and increased quality of life in the long term.
Even considered as a separate pool of data, the results achieved in the homeopathic group were “by all standards, a clinically relevant improvement”.
As the authors concluded:
“We have shown that under homeopathic care, sizeable benefits were achieved for patients’ quality of life, as measured by FACT-G and also for spiritual well-being as measured by the FACIT-Sp. The improvement was clinically relevant and statistically significant. It could also be seen in symptoms of physical and mental fatigue. Thus our data suggest that classical homeopathic care could complement conventional cancer care to the benefit of patients.”
Chatterjee A, Biswas J, Chatterjee AK, Bhattacharya S, Mukhopadhyay B, and Mandal S. Psorinum Therapy in Treating Stomach, Gall Bladder, Pancreatic, and Liver Cancers: A Prospective Clinical Study. Evid Based Complement Alternat Med. 2011: 724743.
Rostock M, Naumann J, Guethlin C, Guenther L, Bartsch HH, Walach H. Classical homeopathy in the treatment of cancer patients – a prospective observational study of two independent cohorts. BMC Cancer. 2011 Jan 17;11(1):19.
Cancer Facts and Figures 2009. American Cancer Society. Available at http://www.cancer.org/downloads/STT/500809web.pdf. Accessed February 5, 2010
Erickson A, Larson C, Shabahang M. Pancreatic Cancer. Available at http://emedicine.medscape.com/article/280605-overview. Accessed February 21, 2010.
Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 2010 Jan;3(1):55-66.
Hui P Zhu,1 Xin Xia,2 Chuan H Yu,2 Ahmed Adnan,3 Shun F Liu,3 and Yu K Du. Application of Weibull model for survival of patients with gastric cancer. BMC Gastroenterol. 2011 Jan 7;11:1
Chatterjee A, Biswas J, Chatterjee AK, Bhattacharya A, Mukhopadhyay BP. A Phase II, Single Arm Clinical Trial Involving an Alternative Cancer Treatment – Psorinum Therapy – in Patients With Non-Small Cell Lung Carcinoma (NSCLC). J Clin Oncol. 2010 vol.28, suppl(15s), abstract 2592.
Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300.